Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs, Inc. (ELAB)
Company Research
Source: GlobeNewswire
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1.Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to submit an Investigational New Drug (IND) application in 2025 that utilizes the licensed asset EL-22, previously called BLS-M221. NEWPORT BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), today highlights results from our licensor’s 2022 preclinical studies evaluating the treatment effect of its recently in-licensed asset, EL-22. EL-22 will primarily be commercialized by Elevai Biosciences, Inc., a biopharmaceutical division of the Company foc
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Labs Inc. Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Inc. Reports First Quarter 2024 Financial Results [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Elevai Labs Inc. Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare [Yahoo! Finance]Yahoo! Finance
ELAB
Sec Filings
- 5/15/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/2/24 - Form 8-K
- ELAB's page on the SEC website